Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

VALIC Company I Health Sciences Fund (VCHSX)

21.68
Net Asset Value
-0.28%
1 Day
+12.56%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.09%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital growth. The fund normally invests at least 80% of its net assets in the common stocks of companies engaged in the research- development- production- or distribution of products or services related to health care- medicine- or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size- the majority of fund assets are expected to be invested in large- and mid-cap companies. The fund may invest up to 35% of its total assets in foreign stocks- which include non-dollar denominated securities traded outside the U.S.

Performance

1 month+2.21% 3 years+8.64%
3 months+0.93% 5 years+20.27%
1 year+25.54% Since inception+11.14%
Data through --

Peer Comparisonvs. Health

 VCHSXCategory
Performance 5-yr return+20.27%+16.80%
Expense ratio1.09%1.20%
Risk 5 year sharpe ratio1.311.11
Net assets$764.5M$220.7M
Average market cap$23.6B$27.3B
Average P/E25.522.4
Portfolio turnover30%30%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyVALIC
Fund manager & tenureZiad Bakri / 1 Years
Minimal initial investment$0.00
Minimum IRA investment--

Holdings

U.S. stock93.42%
International stock5.06%
Other1.06%
Fixed income0.39%
Cash0.07%
Top 5 Sectors
Portfolio weighting
Healthcare 93.57%
Consumer service 1.09%
Industrial materials 0.89%
Financial service 0.35%
Hardware 0.19%
Top 10 Holdings
Portfolio weighting
UNH UnitedHealth6.31%
ISRG Intuitive Surgical4.06%
BDX Becton Dickinson and Co4.02%
VRTX Vertex Pharmaceuticals Inc3.00%
CI Cigna Corp2.96%
SYK Stryker Corp2.26%
A Agilent Technologies Inc2.20%
PBYI Puma Biotechnology Inc2.19%
ALXN Alexion Pharmaceuticals Inc2.06%
HUM Humana Inc2.01%